Oncology News

Bulk ordering and text messaging outreach significantly increased completion rates for mammography breast cancer screening, according to results of two randomized clinical trials published in JAMA Internal Medicine.

Having a primary care provider raises the likelihood of being up to date on cervical cancer screening, regardless of sexual orientation, but the association was greatest among lesbian, gay and bisexual women, according to researchers.

The 10-year interval between screening colonoscopies “could potentially be extended” to 15 years among patients without a family history of colorectal cancer and negative findings for CRC at the first colonoscopy, researchers reported.

Children conceived via fresh or frozen embryo transfer may have increased risk for acute lymphoblastic leukemia compared with children conceived naturally, according to cohort study results published in JAMA Network Open.

In this episode, host Shikha Jain, MD, speaks with Sean Bohen, MD, about how cancer therapies are changing how oncology can be discussed, shifting from clinical to industry work and more.

Women should be screened for breast cancer every other year starting at age 40 years, according to a new recommendation statement from the U.S. Preventive Services Task Force.

Women with breast cancer and germline BRCA pathogenic variants had increased all-cause mortality risk if diagnosis occurred within 10 years postpartum, according to cohort study results published in JAMA Network Open.

BOSTON — There is some evidence that cannabinoids may help with neuropathic pain, chemotherapy-induced nausea/vomiting and MS-associated spasticity, “but it’s not exactly a slam dunk,” a speaker said.

Women with breast cancer living in the most vs. the least disadvantaged neighborhoods had higher risks for breast cancer-specific and overall mortality, according to cohort study results published in JAMA Network Open.

I recently had the pleasure of attending a symposium at the Cleveland Clinic that featured an outstanding review of immune-related adverse events, and I was reminded of how far we have come in the decade since I first became involved in the evolution of this disease class.